Evidence map›Paper›PMID 35264957›Full record

ArticleFrontiers in pharmacology2022

Hsa_Circ_0098181 Suppresses Hepatocellular Carcinoma by Sponging miR-18a-3p and Targeting PPARA.

Yuan-Yuan Luo, Ke-Gong Tao, Yi-Ting Lu, Bin-Bin Li, Kai-Ming Wu, Chen-Hong Ding, Fang-Zhi Yan, Yue Liu, Yong Lin, Xin Zhang and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 16 citations in OpenAlex.

  1. Current medicinal chemistry · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Wnt/β-catenin-driven EMT regulation in human cancers.Cellular and molecular life sciences : CMLS · 2024
    Review
  7. Article
  8. Review
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Yuan-Yuan LuoDepartment of Gastroenterology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.
Ke-Gong TaoDepartment of Gastroenterology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.
Yi-Ting LuDepartment of Gastroenterology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.
Bin-Bin LiDepartment of Gastroenterology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.
Kai-Ming WuDepartment of Gastroenterology, Shanghai Changzheng Hospital, Navy Military Medical University, Shanghai, China.
Chen-Hong DingDepartment of Gastroenterology, Shanghai Changzheng Hospital, Navy Military Medical University, Shanghai, China.
Fang-Zhi YanDepartment of Gastroenterology, Shanghai Changzheng Hospital, Navy Military Medical University, Shanghai, China.
Yue LiuDepartment of Gastroenterology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.
Yong LinDepartment of Gastroenterology, Shanghai Changzheng Hospital, Navy Military Medical University, Shanghai, China.
Xin ZhangDepartment of Gastroenterology, Shanghai Changzheng Hospital, Navy Military Medical University, Shanghai, China.
Xin ZengDepartment of Gastroenterology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.
Shanghai Changzheng Hospital · CNShanghai East Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths, and its incidence is still high in China. This study aimed to investigate the circular RNAs (circRNAs) involved in the development of HCC and elucidate the mechanism. RNA sequencing found 72 downregulated circRNAs and 88 upregulated circRNAs in human HCC tissues, including hsa_circ_0098181, hsa_circ_0072309, hsa_circ_0000831, and hsa_circ_0000231. The reduction of hsa_circ_0098181 was confirmed in eight paired human HCC tissues, hepatoma cell lines, and CCL4/DEN-induced mouse HCC models by RT-qPCR. The FISH assay revealed that hsa_circ_0098181 is mainly located in the cytoplasm of hepatocytes in the paratumor tissues. Further log-rank analysis performed in 91 HCC patients demonstrated that low expression of hsa_circ_0098181 was related to poor prognosis. The plasmid and lentivirus overexpressing hsa_circ_0098181 were delivered into HCC cell lines. After hsa_circ_0098181 was upregulated, the proliferation, invasion, migration, and colony formation of HCC cell lines were inhibited, and the apoptosis was promoted. Moreover, exogenous hsa_circ_0098181 delivery mitigated the tumor formation ability of Huh7 in Balb/C nude mice. The dual-luciferase reporter assay and the RIP assay verified that hsa_circ_0098181 sponged miR-18a-3p to regulate PPARA. In addition, a rescue experiment found miR-18a-3p mimic partly reversed the suppression of hsa_circ_0098181 on proliferation, invasion, and migration of HCC cell lines. In conclusion, hsa_circ_0098181 can repress the development of HCC through sponging miR-18a-3p and promoting the expression of PPARA

Indexed as

hepatocellular carcinoma (HCC)hsa_circ_0098181mir-18a-3pPPARAtherapeutic target

Identifiers

PMID35264957
PMCPMC8899401
OpenAlexW4212822627

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.